Vesugen
Quick summary
A short-peptide (Lys-Glu-Asp) bioregulator studied in blood-vessel cell models. Research focus: short-peptide bioregulators and vascular endothelium. This page leads with SRP's low-and-slow starting dose.
Amino acid sequence (one-letter code): KED
Overview
A short-peptide (Lys-Glu-Asp) bioregulator studied in blood-vessel cell models.
Looking for research material? Simple Research Peptides lists Vesugen (20 mg Vial) for laboratory research use.
Mechanism
Short bioregulator peptides (2–4 amino acids) are proposed to enter cells, interact with DNA or histones, and adjust tissue-specific gene expression. Most of the evidence comes from cell and animal studies by a small number of research groups.
Research areas
- short-peptide bioregulators
- vascular endothelium
Storage & reconstitution
Supplied as a freeze-dried (lyophilized) powder in a sealed vial. Unopened vials are generally kept cold and away from light. Labs usually reconstitute it with bacteriostatic or sterile water, letting the liquid run down the vial wall and swirling gently instead of shaking. The solution is then kept refrigerated.
Recommended starting dose (low and slow)
| Starting dose | Low end of the studied range: 500 mcg; 500 mcg. |
|---|---|
| Frequency | Reported schedules: 500mcg-2mg daily (titrate). |
| Reconstitution | Examples: 20 mg vial + 3 mL water = 6.67 mg/mL; 20mg vial + 3mL diluent (as listed). |
Studied higher doses
Studies have used doses up to the amounts below. Higher doses can be dangerous. Whether a person can reach them safely depends on height, weight, activity level, training and pre-existing conditions. We recommend following the lower starting dose above, and contacting SRP with any questions.
| Highest amount reported in studies | Top of the studied range: 500 mcg; 2 mg. These are range tops, not verified ceilings. Reported amounts vary by 2x or more. |
|---|---|
| Step-up schedules reported | The amount is usually stepped up gradually ('titrated') but none of the ones read gives a step schedule. |
Route and timing
Route: Subcutaneous injection after reconstitution is the route most often described in research protocols.
Timing: Pending - to be added by SRP
Cycle length and repeat
Pending - to be added by SRP
Half-life
Approximate, for Bobby's review: Not well characterized in published research.
Side effects
Pending - to be added by SRP
Suggested bloodwork and monitoring
Draft, for Bobby's review: CBC and comprehensive metabolic panel (kidney and liver function, electrolytes) before starting and again after a few weeks.
Cautions
Pending - to be added by SRP
Reconstitution calculator
Math aid only. It converts the numbers you enter; it is not dosing advice. For research use only. Prefilled with this page's vial size, reconstitution and low-and-slow starting dose where known; change any value.
Frequently asked questions
What is Vesugen studied for?
In research it is studied for short-peptide bioregulators and vascular endothelium. Short bioregulator peptides (2–4 amino acids) are proposed to enter cells, interact with DNA or histones, and adjust tissue-specific gene expression.
How is Vesugen given in research?
Subcutaneous injection after reconstitution is the route most often described in research protocols. See the dosing frequency block on this page for how often.
What amount should a researcher start with?
This page lists SRP's low-and-slow starting dose in the Recommended starting dose section. Higher amounts that appear in studies are listed separately with their safety context. Start with the lower dose and contact SRP with any questions.
Related peptides
Last updated: October 19, 2026